are currently under way, one -the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial -in the United States ( 6 ) and three in Europe ( 7 -9 ) .
The PLCO is evaluating the effect of screening 60-cm fl exible sigmoidoscopy on colorectal cancer mortality when performed once and then repeated 3 -5 years later. The PLCO trial implemented fl exible sigmoidoscopy screening in a manner different from that of the European trials. Biopsies are not part of the PLCO screening protocol; instead, subjects with screen-detected abnormalities are referred to personal physicians for diagnostic follow-up.
Clinical fi ndings for screening fl exible sigmoidoscopy have already been reported for the European trials ( 7 -9 ) . Given the size and unique characteristics (e.g., geographically diverse study population, numerous fl exible sigmoidoscopy examiners recruited from various clinical backgrounds, and diagnostic follow-up managed by community-based practitioners working in non-research clinical settings) of the PLCO trial, it is capable of approximating the results that could be expected from a screening fl exible sigmoidoscopy intervention targeting the general U.S. population. In this study, we report clinical results from the initial PLCO screening fl exible sigmoidoscopy examination.
S UBJECTS AND M ETHODS
The PLCO Cancer Screening Trial, which is a multicenter randomized clinical trial sponsored by the National Cancer Institute, is testing the effectiveness of early prostate, lung, colorectal, and ovarian cancer detection with 1) digital rectal examination and blood prostate-specifi c antigen (PSA) testing, 2) chest X-ray, 3) 60-cm fl exible sigmoidoscopy, and 4) transvaginal ultrasound, blood cancer antigen (CA)-125 testing, respectively, versus usual care ( 6 ) . Ten PLCO screening centers (Birmingham, AL; Denver, CO; Detroit, MI; Honolulu, HI; Marshfi eld, WI; Minneapolis, MN; Pittsburgh, PA; Salt Lake City, UT; St. Louis, MO; and Washington, DC) contributed data to this analysis.
Trial Subjects
Beginning in November 1993 and ending in July 2001, the PLCO trial enrolled men and women 55 -74 years of age who had no prior history of prostate, lung, colorectal, or ovarian cancer. Criteria for exclusion included current treatment for cancer (other than basal cell and squamous cell skin cancer); prior total colectomy, pneumonectomy, prostatectomy, or bilateral oophorectomy (with bilateral oophorectomy dropped as an exclusion criterion beginning in 1996); participation in another cancer screening or primary prevention study; and recent use of fi nasteride (Proscar) or tamoxifen (Nolvadex). Beginning in April 1995, the PLCO trial excluded men who reported more than one serum PSA test and men and women who reported any lower gastrointestinal procedure (proctoscopy, sigmoidoscopy, barium enema, or colonoscopy) within 3 years before study enrollment.
The primary method for recruiting study subjects involved mailing informational brochures and letters of invitation to ageeligible individuals identifi ed on public, commercial, or screening center-specifi c mailing lists. Three screening centers initially used a dual consent procedure that was designed to limit, in the control group, knowledge about the screening tests being offered to the intervention group. Under the dual consent procedure, screening centers recruited subjects who agreed only to a baseline questionnaire and periodic contacts to determine morbidity and mortality endpoints. Random assignment of the subjects to either the control or intervention group then occurred without any other additional consent. After randomization, subjects assigned to the intervention group were asked to sign a second consent form that mentioned the screening procedures under investigation. Although three screening centers evaluated the dual consent procedure, all centers eventually abandoned this approach in favor of a single consent procedure, in which prior consent for both randomization into trial arms and cancer screening was obtained. Only one screening center recruited a meaningful number of subjects under the dual consent procedure. The study coordinating center managed the randomization scheme, which was blocked according to screening center, sex, and age.
Screening centers obtained written informed consent from each subject. The institutional review boards at each of the screening centers listed above reviewed the PLCO protocol and approved the use of human subjects.
Baseline Characteristics
A baseline questionnaire was given to each participant on entry into the study. The questionnaire recorded personal sociodemographic characteristics (e.g., age, race, sex, marital status, and education), cancer family history, personal medical history (including history of colorectal polyp), cigarette-smoking history, and cancer screening history within 3 years.
Flexible Sigmoidoscopy Procedure
Physician and non-physician examiners, who were all centrally registered, followed standardized procedures to perform and record results from the 60-cm fl exible sigmoidoscopy examination. Examiners used depth of insertion, adequacy of bowel preparation, and primary visual fi ndings to place each sigmoidoscopy examination into one of three mutually exclusive result categories. The positive result category signifi ed a fi nding of a polyp or mass. The inadequate result category signifi ed a <50-cm depth of insertion or visual inspection limited to <90% of the mucosal surface due to inadequate bowel preparation, with no detection of a polyp or mass. The negative result category signifi ed a technically adequate examination with no detection of a polyp or mass.
Subjects experiencing a technically inadequate sigmoidoscopy could return at a later date for a second examination. By protocol, a repeat sigmoidoscopy was to be offered to individuals experiencing an inadequate examination due to incomplete bowel preparation. A repeat procedure was not routinely offered to individuals with limited bowel examination due to pain or discomfort. In 7522 cases of technical inadequacy on an initial examination, 632 (8.4%) subjects returned for a second fl exible sigmoidoscopy examination; after that examination, a total of 7099 cases of technical inadequacy remained. All subjects were classifi ed according to the result of their last sigmoidoscopy examination.
Using visual size estimates at sigmoidoscopy, PLCO examiners recorded the maximum dimensions for the four largest polyps or masses detected at the baseline (T0) screening fl exible sigmoidoscopy examination. The PLCO protocol did not prohibit or preclude colonic biopsy or polypectomy at screening flexible sigmoidoscopy. However, the PLCO screening centers and examiners chose, with rare exception, not to biopsy or remove polyps or masses during the PLCO screening fl exible sigmoidoscopy examination. Instead, the PLCO staff referred subjects with screen-detected abnormalities to their personal physicians for diagnostic follow-up. PLCO staff debriefed subjects at the end of each screening examination and communicated the sigmoidoscopy test results. Letters and reports that were mailed later to each participant and a personal physician of record communicated all PLCO test results, including detailed sigmoidoscopy fi ndings and reinforced recommendations for physician follow-up when appropriate.
The PLCO trial protocol did not include study-wide standards or guidelines for the diagnostic evaluation of screen-detected abnormalities. However, study subjects and personal physicians were given access to screening center consultants, who could respond to questions and deliver advice regarding diagnostic approaches. The PLCO tracked subjects for at least 12 months after screening and identifi ed, requested, and abstracted medical records pertaining to subsequent diagnostic work-ups. Information abstracted from medical records included the occurrence and date of follow-up fl exible sigmoidoscopy and/or colonoscopy examinations, the anatomic location, and the size (as recorded on clinical endoscopy reports) and histology of removed polyps and masses. Dates of diagnosis, TNM clinical stages ( 10 ) , and TNM pathologic stages were collected for subjects with invasive colorectal cancer.
By defi nition, the advanced adenoma classifi cation included cases of villous or tubulovillous adenoma, large ( ≥ 1.0 cm) adenoma, or severe or high-grade dysplasia. Analyses treated designations of carcinoma in situ and severe dysplasia as synonymous terms. The PLCO colorectal cancer endpoint excluded cancers involving the anus or anal canal but included carcinoid tumors involving the appendix, colon, or rectum. To estimate diagnostic consequences and yields, analyses tabulated lower endoscopic procedures and colorectal cancer and adenoma diagnoses occurring within 365 days of a positive PLCO screening fl exible sigmoidoscopy examination.
Statistical Analysis
We used Cochran -Mantel -Haenszel statistics and logistic regression (SAS System for Windows Release 8.01, Cary, NC) to evaluate the statistical signifi cance of differences in proportions according to sex (in both unadjusted and age-adjusted analyses), sex-specifi c differences according to age, and sex-specifi c trends according to age. Subsequent text and tables present results according to 5-year age groupings (55 -59, 60 -64, 65 -69, and 70 -74 years of age at study enrollment). In large studies, such as the PLCO screening trial, small absolute differences can be statistically signifi cant. Unless otherwise indicated, every mention of an association involving sex or age had a P of <.001. All statistical tests were two-sided.
R ESULTS
Using primarily mass mailings sent to age-eligible community residents, the PLCO trial recruited and randomly assigned 154 942 individuals aged 55 -74 years to either the control group (77 477 individuals) or the intervention group (77 465 individuals) ( Fig. 1 ) . All results that are presented in this report pertain to the intervention subjects. Table 1 shows the distribution of the subjects according to sex and age at enrollment and shows the prevalence of selected baseline characteristics. Subjects were diverse with respect to sex (50.5% female), age, race (11.2% black, Hispanic, or other race), educational status (7.3% had less than a high school diploma and 34.4% were college graduates), and self-reported family history of colorectal cancer in a fi rstdegree relative (9.7%). Overall, 7.4% of subjects reported a * PI/AI = Pacifi c Islander/American Indian; FOBT = one or more fecal occult blood tests within the previous 3 years; Lower GI = one or more lower gastrointestinal procedures (sigmoidoscopy, colonoscopy, or barium enema) within the previous 3 years.
† Total number of subjects with data = 75 004. ‡ Total number of subjects with data = 72 112. § Total number of subjects with data = 75 592. || Total number of subjects with data = 75 585.
personal history of colorectal polyp, 38.7% of subjects reported having one or more FOBTs within 3 years of study entry, and 12.9% reported one or more lower gastrointestinal procedures (sigmoidoscopy, colonoscopy, or barium enema) within 3 years of study entry ( Table 1 ) . Men reported a polyp history (8.7%) and recent lower gastrointestinal testing (16.0%) more frequently than did women (6.1 and 9.9%, respectively; data not shown). However, women reported a recent FOBT (42.2%) more frequently than did men (35.1%). When analyzed by 5-year age grouping (i.e., 55 -59, 60 -64, 65 -69, and 70 -74 years of age), the frequencies of a personal history of colorectal polyps (4.7%, 7.5%, 9.3%, and 11.1%), of recent FOBT (31.8%, 39.3%, 43.5%, and 46.2%), and of recent lower gastrointestinal testing (3.4%, 14.8%, 19.1%, and 21.7%) increased with age (data not shown).
With respect to participant compliance, 64 658 (83.5%) subjects underwent the baseline screening fl exible sigmoidoscopy examination ( Fig. 1 ). Women were more likely than men to decline sigmoidoscopy (19.2% versus 13.8%). Nonacceptance of sigmoidoscopy increased with each age grouping among women (17.6%, 18.2%, 20.2%, and 23.6%) but not among men (14.1%, 13.3%, 13.5%, and 15.1%, P trend = .31; P <.001 age * sex interaction).
According to the PLCO defi nitions, the sigmoidoscopy examination was inadequate in 7099 subjects (11.0% of 64 658; Table 2 ). An inadequate sigmoidoscopy examination occurred more frequently in women than in men (15.2% versus 7.0%) and increased with each age grouping in both women (13.9%, 14.4%, 16.3%, and 18.8%) and men (6.2%, 6.5%, 7.7%, and 8.7%; P = .95 age * sex interaction).
PLCO examiners discovered a polyp or mass (corresponding to a positive screening test result) in 15 150 (23.4%) out of 64 658 subjects examined ( Table 2 ) . Positive screens were less frequent in women than in men (18.4% versus 28.3%). Positive screens increased with age in both men (26.2%, 29.4%, 29.9%, and 27.7%; Table 2 ) and women (16.3%, 18.7%, 20.3%, and 19.9%; Table 2 ), although statistical testing suggested smaller differences between men and women with increased age ( P = .019 age * sex interaction).
Over all age groups, the fi nding of at least one large ( ≥ 1.0 cm) polyp or mass occurred less frequently among women than in men (2.1% versus 4.2%; Table 2 ), as did the fi nding of at least one 0.5-cm or larger polyp or mass (7.5% versus 12.8%). Among women and men considered separately, the prevalence of polyps of 0.5 -0.9 cm and of ≥ 1.0 cm increased with age ( Table 2 ) . Table 3 summarizes the baseline screening fl exible sigmoidoscopy results by age-sex subgroup. We analyzed the proportions of enrolled individuals who accepted screening; proportions of screened individuals with a positive screen; proportions of positive screens with diagnostic follow-up (i.e., cancer diagnosis, sigmoidoscopy, colonoscopy, or lower endoscopy not otherwise specifi ed) within 365 days of screening; positive predictive values for cancer, advanced adenoma, and non-advanced adenoma in individuals with diagnostic follow-up subsequent to the screen detection of a polyp or mass; and cancer and adenoma yields, expressed both as proportions of all intervention subjects and as proportions of screened intervention subjects.
Estimates of screening yield refl ected the type of diagnostic follow-up received. Follow-up varied according to age and sex ( Table 3 ) and according to the size of the largest screendetected polyp or mass -that is, subjects with only small screendetected polyps were less likely than subjects with at least one larger polyp to have diagnostic follow-up. Women and men with only small polyps (<0.5 cm) had follow-up sigmoidoscopy or colonoscopy in 69.1% (95% CI = 67.5% to 70.6%) and 65.4% (95% CI = 64.1% to 66.7%) of cases, respectively, whereas women and men with at least one larger polyp ( ≥ 0.5 cm) had follow-up sigmoidoscopy or colonoscopy in 86.0% (95% CI = 84.6% to 87.4%) and 81.0% (95% CI = 79.8% to 82.2%) of cases, respectively (data not shown). In approximately 6% of cases, diagnostic follow-up was in the form of repeat sigmoidoscopy without colonoscopy. Depending on sex and age, cancer yields ranged between 0.9 and 4.7 per 1000 subjects, cancer or advanced adenoma yields ranged between 15.8 and 46.7 per 1000 intervention subjects, and cancer or adenoma (advanced or non-advanced) detection yields ranged between 41.7 and 111.2 per 1000 intervention subjects ( Table 3 ) . Cancer and adenoma yields were lower in women than in men, whether they were calculated in terms of enrolled women and men (cancer yield: 1.5 cases in women per 1000 screened versus 3.3 cases in men; cancer or adenoma yield: 51.5 cases in women per 1000 screened versus 100.5 cases in men; Table 3 ) or calculated in terms of screened women and men (cancer yield: 1.8 cases in women per 1000 screened versus 3.8 cases in men; cancer or adenoma yield: 63.8 cases in women per 1000 screened versus 116.6 cases in men; Table 3 ). When women and men were analyzed together (data not shown), cancer and adenoma yields increased with age, whether calculated in terms of enrolled subjects (cancer yield among those aged 55 -59, 60 -64, 65 -69, and 70 -74 years: 1.4, 2.7, 2.9, and 3.2 cases per 1000, respectively; cancer or adenoma yield: 63.7, 78.9, 86.7, and 80.4 cases per 1000, respectively) or calculated in terms of screened subjects (cancer yield: 1.7, 3.2, 3.5, and 4.0 cases per 1000, respectively; cancer or adenoma yield: 75.7, 93.6, 104.2, and 99.8 cases per 1000, respectively).
The frequency and relative odds of cancer or adenoma among screened subjects according to sex and age are shown in Table 4 . Overall, the age-adjusted odds of cancer or adenoma among screened men relative to that among screened women was 1.92 (95% CI = 1.82 to 2.04). Male sex moderated the effects of age on screen detection of cancer or adenoma ( P = .002 age * sex interaction). Relative to 55-to 59-year-old women, the odds of cancer or adenoma among screened women aged 60 -64 years, 65 -69 years, and 70 -74 years were 1.26 (95% CI = 1.12 to 1.42), A total of 185 PLCO intervention subjects were diagnosed with a colorectal carcinoma (n = 169) or carcinoid tumor (n = 16) within 12 months (365 days) of fl exible sigmoidoscopy screening. In two cases, carcinoid tumors were metastatic at the time of diagnosis. Table 5 summarizes the anatomic site location in the 169 subjects with colorectal carcinoma. Carcinoma location was distal in 139 cases (82.2%; 2, 6, 78, 13, and 40 in the splenic fl exure, descending colon, sigmoid colon, rectosigmoid junction, and rectum, respectively; Table 5 ), proximal in 25 cases (14.8%; 8, 4, 3, and 10 in the cecum, ascending colon, hepatic 
D ISCUSSION
The PLCO Cancer Screening Trial offers a unique opportunity to examine the acceptance and yield of screening fl exible sigmoidoscopy in a large at-risk population. By virtue of the unprecedented size of the cohort, the broad geographic representation, and the diagnostic follow-up that occurred within a clinical context, both at the primary care and the specialist level, with diagnostic follow-up performed by hundreds of different endoscopists, the results of the PLCO screening trial offer a benchmark for screening fl exible sigmoidoscopy in the United States.
Discussion of the broader implications of the baseline colorectal cancer screening results from the PLCO trial must take into account certain aspects of the PLCO screening intervention, including the conscious decision not to include colonic biopsy or polyp excision as an integrated part of the screening fl exible sigmoidoscopy examination. Persuasive concerns underlying this decision included challenges related to both fi nancial costs and examiner training. The PLCO encouraged strategies to improve effi ciencies and to reduce costs directly associated with the screening examination procedures. Relevant strategies included simultaneous screening for prostate, lung, colorectal, and ovarian cancer; use of non-physician examiners; economies of scale (i.e., effi ciencies created by having a few screening centers perform many examinations as opposed to having many screening centers perform a few screening examinations); and other organizational steps designed to reduce personnel and overhead costs. Colonic biopsy and polypectomy were precluded as integrated parts of the screening experience because they were seen as threats to effi ciency and because of concerns regarding the clinical credentials of non-physician examiners. These same issues, pertaining to cost, feasibility, and organization, clearly pertain to mass screening programs in general.
Arguments favoring biopsy or polypectomy at screening are based, at least in part, on the belief that hyperplastic polyps do not require follow-up colonoscopy. Imperiale et al. ( 11 ) have evaluated trade-offs, in terms of detecting advanced proximal neoplasia relative to colonoscopy resource use, associated with three alternative strategies -colonoscopy for those with any distal polyp on screening sigmoidoscopy, colonoscopy for only those with biopsy-verifi ed adenoma on screening sigmoidoscopy, and colonoscopy for everyone without preliminary screening sigmoidoscopy. With respect to fl exible sigmoidoscopy screening, the fi rst strategy may be most commonly used in primary care settings, whereas the second strategy may be more commonly favored by professional organizations ( 11 ) . In any case, relative to colonoscopy for any distal polyp, restricting colonoscopy to those with biopsy-verifi ed adenoma may reduce the colonoscopy need by approximately 50% and the detection of proximal advanced neoplasia by 25% ( 11 ) .
A high proportion of subjects (83.5%) accepted the initial PLCO screening fl exible sigmoidoscopy examination, refl ecting the extent to which screening can be implemented in a motivated population ( 12 -15 ) . In the PLCO trial, sigmoidoscopy was adequate (depth of insertion beyond 50 cm and visualization of 90% of the intestinal mucosa) in 89.0% of subjects, a measure of adequacy similar to that seen in European trials ( 7 -9 ) . These results also compare favorably with the 40-to 50-cm average insertion depths reported in the past ( 16 ) . However, a relatively high proportion of women, especially 70-to 74-year-old women (23.6%), did not accept screening sigmoidoscopy. In addition, sigmoidoscopy was often inadequate in women, especially older women. Perceptions by women regarding the tolerability of fl exible sigmoidoscopy may contribute to their lower acceptance of screening. Women report pain or discomfort from fl exible sigmoidoscopy more often than do men ( 17 ) and are more likely to have an inadequate exam. Inadequate exams, in turn, are more likely to be associated with advanced lesions detected at a later time ( 18 ) . Consequently, colonoscopy may be preferred to fl exible sigmoidoscopy to achieve adequate screening in older women.
Screening fl exible sigmoidoscopy detected one or more polyps, particularly small polyps, in 23.4% of screened subjects. The results from diagnostic follow-up sigmoidoscopy or colonoscopy depended on the size of the index polyp detected at screening. For example, diagnostic follow-up documented cancer or adenoma in 83.0% of individuals in whom a large polyp or mass ( ≥ 1.0 cm) was detected by flexible sigmoidoscopy screening (data not shown). In addition, the prevalences of large ( ≥ 1.0 cm), intermediate (0.5 -0.9 cm), or any size polyp or mass were consistently and substantially greater in men than in women and generally increased with age, especially in women. As a corollary of higher polyp prevalence in men, cancer and advanced adenoma diagnoses were twice as frequent in men, consistent with results from other, smaller case series ( 19 -22 ) .
Data on endoscopic colorectal follow-up were lacking for approximately 25% of subjects with a screen-detected polyp or mass. Diagnostic follow-up may not occur for many reasons, both participant-and physician-related, including personal choice, lack of health insurance, physician recommendation, and failure to retrieve the data. Diagnostic follow-up was much less frequent among subjects with small (<0.5 cm) colorectal polyps than in those with larger ( ≥ 1.0 cm) polyps. The rate of follow-up for subjects with larger polyps in our study was similar to that in a large group-model health maintenance organization, in which 83.5% of patients with a fi nding of multiple distal adenomas or a distal advanced adenoma at screening sigmoidoscopy had colonoscopy follow-up within 6 months ( 23 ) . Because the PLCO follow-up procedures occurred as part of regular medical care, our observations constitute a realistic picture of the results expected from a large-scale U.S. fl exible sigmoidoscopy screening program.
Our diagnostic yields for fl exible sigmoidoscopy compare favorably with historical sigmoidoscopy standards ( 19 , 24 , 25 ) . Table 6 examines yields observed in the PLCO trial relative to the yields observed in concurrent European studies ( 7 -9 ) . The subjects in the European studies were younger, on average, than those in the PLCO study; in addition, unlike the PLCO study, the European studies integrated biopsy into the fl exible sigmoidoscopy screening procedure and conducted colonoscopy according to prespecifi ed criteria and as a study-directed follow-up activity. For example, the United Kingdom study ( 7 ) required colonoscopy referral for individuals with highrisk findings on screening sigmoidoscopy, with high risk being defi ned as a polyp of 1.0 cm or larger, three or more adenomas, adenoma with tubulovillous or villous histology, severe dysplasia or malignancy, or 20 or more hyperplastic polyps above the distal rectum ( 7 ) . By comparison, the PLCO trial referred subjects with any visible polyp or mass to personal physicians for evaluation and management. Therefore, colonoscopy use in the PLCO study refl ected local medical practice standards, physician practice patterns, access to medical care, and subject compliance with recommendations to seek medical care. * The screening intervention in the United Kingdom Flexible Sigmoidoscopy Screening Trial (UKFSST) and the SCORE trial included " once-only " fl exible sigmoidoscopy screening for colorectal cancer (the SCORE trial). Norwegian Colorectal Cancer Prevention (NORCCAP) trial included once-only fl exible sigmoidoscopy in one-half of the intervention group and fl exible sigmoidoscopy plus fecal occult blood testing in the other half. The screening intervention in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer trial included initial and repeat fl exible sigmoidoscopy, in addition to periodic screening for prostate, lung, and ovarian cancer.
† Lower gastrointestinal procedure; in PLCO, exclusion applied after April 1995. ‡ For SCORE, sex and age expressed as percentage of persons enrolled; for other three studies, sex and age expressed as percentage of persons screened. § Expressed as percentage of persons screened. || For PLCO, colonoscopy documented within one year of screen; for other three studies, colonoscopy completed as an integrated study procedure. ¶ For PLCO, in subjects without distal cancer. # For UKFSST, advanced distal lesions defi ned as a ≥ 1.0-cm polyp, three or more adenomas, tubulovillous or villous adenoma, severe dysplasia, malignancy, or 20 or more hyperplastic polyps beyond distal rectum, as determined by screening sigmoidoscopy and associated biopsies; for SCORE, advanced distal lesions defi ned as a ≥ 1.0-cm adenoma, tubulovillous or villous adenoma, or severe dysplasia, as determined by screening sigmoidoscopy and associated biopsies; for PLCO, advanced distal lesions defi ned as a ≥ 1.0-cm adenoma, tubulovillous or villous adenoma, or severe dysplasia in rectum, sigmoid colon, or descending colon or within 50 cm of anal verge (if segment not specifi ed), as determined by diagnostic follow-up procedures completed within one year of screening. ** For UKFSST, proximal to sigmoid colon; for SCORE, proximal to the descending colon or in the descending colon, if not detected at screening sigmoidoscopy; for PLCO, segment proximal to descending colon or more than 50 cm from anal verge (if segment not specifi ed).
† † Advanced adenoma defi ned as ≥ 1.0 cm adenoma, tubulovillous or villous adenoma, or severe dysplasia. ‡ ‡ For PLCO, in subjects without proximal cancer. The PLCO study documented subsequent colonoscopy in 16.2% of screened subjects, similar to the 19.5% result observed in Norway ( 9 ) but higher than the 5.0% and 7.8% results observed in the United Kingdom ( 7 ) and Italy ( 8 ) , respectively. The UK and Italian studies used similar protocols and procedures for colorectal cancer screening and diagnosis, with the Italian study design based on a United Kingdom precedent. The liberal colonoscopy referral criteria implemented in Norway, relative to the more restrictive criteria enforced in the United Kingdom and Italy, account for these different colonoscopy rates. Cancer and adenoma yields varied across studies ( Table 6 ). Cancer yields were relatively high in Italy, whereas adenoma yields were relatively high in Norway. Differences in the prevalence of advanced adenoma may relate to the different defi nitions for advanced adenoma used in the different studies ( Table 6 ). Variable adenoma and cancer yields across studies may also relate to factors associated with study participation (e.g., prior screening behaviors) and to population-specifi c differences with respect to underlying risk for colorectal neoplasia.
Subjects with procedures following an abnormal screening, without cancer or adenoma detected, include both subjects with other polypoid abnormalities (e.g., hyperplastic polyp) and subjects without any abnormality detected at all. The latter result, in which a follow-up diagnostic colonoscopy fails to confi rm the presence of polypoid abnormalities observed at screening, refl ects both the variability of decision thresholds used by different examiners to report mucosal fi ndings and the possibility of missing lesions during diagnostic follow-up. Sigmoidoscopy positivity rates are known to vary according to examiner ( 19 , 26 -28 ) . For example, in 18.5% of 249 subjects who received backto-back fl exible sigmoidoscopy in one study ( 29 ) , a second examiner detected one or more polyps missed by the initial examiner. Similarly, in tandem colonoscopy studies, individual examiners missed polyps smaller than 0.5 cm up to 27% of the time ( 30 ) . Detection of polypoid abnormalities on follow-up sigmoidoscopy or colonoscopy was associated with the size of the largest index abnormality on initial screening. Hence, smaller polyps are easily missed and are particularly subject to variable interpretation.
In the PLCO trial, 80% of colorectal cancers associated with positive sigmoidoscopy were discovered in the distal colon, as one might expect from a procedure that examines the distal colon primarily. However, the induction of colonoscopy by screening, enables evaluation and treatment of the proximal colon. In accordance with the frequency of follow-up colonoscopy, proximal adenoma yields from initial sigmoidoscopy and associated follow-up were greater in the PLCO study than in the UK and Italian studies ( Table 6 ) .
Diagnostic stage is an important intermediate outcome for cancer screening studies. In the PLCO study, early-stage cancer (i.e., stage I or II) occurred in nearly 77% of cases associated with positive sigmoidoscopy. However, diagnostic stage distribution cannot be used to infer mortality benefi t, and judgments regarding the colorectal cancer-specifi c mortality benefi t from screening fl exible sigmoidoscopy require long-term follow-up.
Finally, volunteers to clinical trials are not necessarily representative of the general population. Relative to the general population, the PLCO trial included better-educated individuals and fewer individuals from ethnic and racial minority groups. However, given the size and diversity of the PLCO study population, the number and geographic distribution of the PLCO cancer screening centers, and the reliance on community physician referral for completion of diagnostic evaluations, the screening sigmoidoscopy fi ndings and subsequent diagnostic results reported here can be viewed as an approximation of the potential of screening fl exible sigmoidoscopy in a real-world setting. By providing age-and gender-specifi c fi ndings, we offer general benchmarks for what could be expected from large-scale implementation of screening sigmoidoscopy in the United States.
